InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.55
(
-0.28%
)
Bitcoin
65,144.94
(
0.01%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: genisi post# 131091

Monday, 05/21/2012 2:39:16 PM

Monday, May 21, 2012 2:39:16 PM

Post# of 252254

Given the significant reduction in death and the absolute major bleeding rates, I think the 2.5mg rivaroxaban dose has a good risk/reward profile in ACS.

Karen A. Hicks, M.D., the FDA reviewer seems to agree with this. From page 16 in the briefing docs:

I recommend approval of XARELTO® (2.5 mg po BID) to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS)
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up